Compare Stocks: SRZN, AVTX, WVE, and JANX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVTX Avalo Therapeutics	$19.74 +2.4%	$18.68	$8.65 ▼ $24.27	$1.03B	0.8	739,357 shs	1.02 million shs
JANX Janux Therapeutics	$18.68 +0.4%	$15.85	$12.12 ▼ $35.34	$1.14B	2.5	689,028 shs	1.07 million shs
SRZN Surrozen	$23.36 -2.5%	$23.14	$10.73 ▼ $35.00	$278.30M	0.52	282,370 shs	218,968 shs
WVE WAVE Life Sciences	$5.25 +2.5%	$5.80	$5.01 ▼ $21.73	$1.01B	-1.26	3.40 million shs	2.41 million shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVTX Avalo Therapeutics	-2.82%	-3.41%	+4.50%	+20.29%	+95.04%
JANX Janux Therapeutics	+6.96%	+14.39%	+21.33%	+29.17%	-23.46%
SRZN Surrozen	-0.08%	+0.80%	+21.49%	-8.41%	+113.64%
WVE WAVE Life Sciences	-3.21%	+0.59%	-11.88%	-19.75%	-49.56%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVTX Avalo Therapeutics	$19.74 +2.4%	$18.68	$8.65 ▼ $24.27	$1.03B	0.8	739,357 shs	1.02 million shs
JANX Janux Therapeutics	$18.68 +0.4%	$15.85	$12.12 ▼ $35.34	$1.14B	2.5	689,028 shs	1.07 million shs
SRZN Surrozen	$23.36 -2.5%	$23.14	$10.73 ▼ $35.00	$278.30M	0.52	282,370 shs	218,968 shs
WVE WAVE Life Sciences	$5.25 +2.5%	$5.80	$5.01 ▼ $21.73	$1.01B	-1.26	3.40 million shs	2.41 million shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVTX Avalo Therapeutics	-2.82%	-3.41%	+4.50%	+20.29%	+95.04%
JANX Janux Therapeutics	+6.96%	+14.39%	+21.33%	+29.17%	-23.46%
SRZN Surrozen	-0.08%	+0.80%	+21.49%	-8.41%	+113.64%
WVE WAVE Life Sciences	-3.21%	+0.59%	-11.88%	-19.75%	-49.56%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVTX Avalo Therapeutics	2.86	Moderate Buy	$45.10	128.47% Upside
JANX Janux Therapeutics	2.67	Moderate Buy	$36.46	95.19% Upside
SRZN Surrozen	2.71	Moderate Buy	$45.00	92.64% Upside
WVE WAVE Life Sciences	2.81	Moderate Buy	$22.53	329.13% Upside

Current Analyst Ratings Breakdown

Latest SRZN, AVTX, WVE, and JANX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/24/2026	JANX Janux Therapeutics	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Peer Perform ➝ Outperform	$23.00
8/24/2026	JANX Janux Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/20/2026	SRZN Surrozen	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$51.00
8/20/2026	SRZN Surrozen	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$51.00
8/19/2026	WVE WAVE Life Sciences	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/11/2026	AVTX Avalo Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/10/2026	SRZN Surrozen	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$44.00
8/7/2026	JANX Janux Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$35.00
8/7/2026	AVTX Avalo Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Buy	$50.00 ➝ $48.00
8/7/2026	JANX Janux Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$58.00 ➝ $55.00
8/7/2026	AVTX Avalo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$35.00 ➝ $30.00

(Data available from 8/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVTX Avalo Therapeutics	$60K	17,644.27	N/A	N/A	$8.37 per share	2.36
JANX Janux Therapeutics	$10M	114.21	N/A	N/A	$15.18 per share	1.23
SRZN Surrozen	$3.48M	77.93	N/A	N/A	($18.83) per share	-1.24
WVE WAVE Life Sciences	$42.73M	24.21	N/A	N/A	$2.30 per share	2.28

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVTX Avalo Therapeutics	-$78.26M	-$4.37	N/A	N/A	N/A	N/A	-58.03%	-48.22%	11/5/2026 (Estimated)
JANX Janux Therapeutics	-$113.62M	-$1.64	N/A	N/A	N/A	N/A	-11.89%	-11.13%	11/5/2026 (Estimated)
SRZN Surrozen	-$242.03M	-$40.55	N/A	N/A	N/A	-2,885.33%	N/A	-93.62%	11/6/2026 (Estimated)
WVE WAVE Life Sciences	-$204.38M	-$1.09	N/A	N/A	N/A	-309.73%	-50.36%	-40.06%	11/9/2026 (Estimated)

Latest SRZN, AVTX, WVE, and JANX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	AVTX Avalo Therapeutics	-$0.5827	-$0.83	-$0.2473	-$0.83	N/A	N/A
8/6/2026	Q2 2026	JANX Janux Therapeutics	-$0.2513	-$0.35	-$0.0987	-$0.35	$19.08 million	$10.27 million
8/6/2026	Q2 2026	SRZN Surrozen	-$1.29	-$0.41	+$0.88	-$0.41	$0.47 million	$5.00 million
7/30/2026	Q2 2026	WVE WAVE Life Sciences	-$0.2998	-$0.34	-$0.0403	-$0.34	$7.45 million	$2.27 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVTX Avalo Therapeutics	N/A	N/A	N/A	N/A	N/A
JANX Janux Therapeutics	N/A	N/A	N/A	N/A	N/A
SRZN Surrozen	N/A	N/A	N/A	N/A	N/A
WVE WAVE Life Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVTX Avalo Therapeutics	N/A	19.31	19.31
JANX Janux Therapeutics	N/A	16.35	16.35
SRZN Surrozen	N/A	12.14	12.14
WVE WAVE Life Sciences	N/A	9.99	9.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVTX Avalo Therapeutics	87.06%
JANX Janux Therapeutics	75.39%
SRZN Surrozen	66.57%
WVE WAVE Life Sciences	89.73%

Insider Ownership

Company	Insider Ownership
AVTX Avalo Therapeutics	4.46%
JANX Janux Therapeutics	7.90%
SRZN Surrozen	31.74%
WVE WAVE Life Sciences	24.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVTX Avalo Therapeutics	40	53.63 million	51.24 million	Not Optionable
JANX Janux Therapeutics	30	61.14 million	56.31 million	Optionable
SRZN Surrozen	80	11.61 million	7.93 million	Not Optionable
WVE WAVE Life Sciences	240	197.05 million	149.17 million	Optionable

SRZN, AVTX, WVE, and JANX Headlines

Recent News About These Companies

WAVE Life Sciences (NASDAQ:WVE) Downgraded by Zacks Research to "Hold"

August 21, 2026 | marketbeat.com

WAVE Life Sciences (NASDAQ:WVE) Director Sells $23,222.64 in Stock

August 14, 2026 | insidertrades.com

Ken Takanashi Sells 3,864 Shares of WAVE Life Sciences (NASDAQ:WVE) Stock

August 13, 2026 | marketbeat.com

Insider Selling: WAVE Life Sciences (NASDAQ:WVE) Director Sells $42,070.00 in Stock

August 13, 2026 | marketbeat.com

WAVE Life Sciences (NASDAQ:WVE) Director Adrian Rawcliffe Sells 12,700 Shares

August 13, 2026 | marketbeat.com

Wave Life Sciences: A $1 Billion RNA-Medicine Bargain Ripe for Pharma Takeover

August 13, 2026 | 247wallst.com

Wave Life Sciences: An Fairly Valued RNA Opportunity

August 12, 2026 | seekingalpha.com

WAVE Life Sciences (NASDAQ:WVE) Hits New 52-Week Low - Here's What Happened

August 12, 2026 | marketbeat.com

Wave Life Sciences Ltd. (WVE) Presents at Bank of America SMID Cap Virtual Conference Transcript

August 11, 2026 | seekingalpha.com

WAVE Life Sciences (NASDAQ:WVE) Stock Price Down 6.8% - Should You Sell?

August 11, 2026 | marketbeat.com

Wave Life Sciences Completes Redomiciliation to Delaware

August 10, 2026 | finance.yahoo.com

WAVE Life Sciences (NASDAQ:WVE) Shares Gap Up - Here's Why

August 10, 2026 | marketbeat.com

Wave Life Sciences Announces Completion of Redomiciliation to Delaware

August 10, 2026 | globenewswire.com

WAVE Life Sciences Ltd. (NASDAQ:WVE) Receives Consensus Rating of "Moderate Buy" from Brokerages

August 10, 2026 | marketbeat.com

Did U.S. Redomiciliation and Mixed 1H 2026 Results Just Shift Wave Life Sciences' (WVE) Investment Narrative?

August 7, 2026 | finance.yahoo.com

WAVE Life Sciences Ltd. $WVE Shares Purchased by Renaissance Technologies LLC

August 7, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Wave Life Sciences (WVE), BrightSpring Health Services, Inc. (BTSG) and AgomAb Therapeutics NV ADR (AGMB)

August 5, 2026 | theglobeandmail.com

Wave Life Sciences Announces Expected Completion Date for Redomiciliation to Delaware

August 5, 2026 | globenewswire.com

Mizuho Lowers WAVE Life Sciences (NASDAQ:WVE) Price Target to $23.00

August 4, 2026 | marketbeat.com

Wave Life Sciences to Present at Upcoming Investor Conferences

August 4, 2026 | globenewswire.com

HC Wainwright Issues Optimistic Outlook for WVE Earnings

August 4, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRZN, AVTX, WVE, and JANX Company Descriptions

Avalo Therapeutics NASDAQ:AVTX

$19.74 +0.47 (+2.44%)

Closing price 04:00 PM Eastern

Extended Trading

$19.75 +0.01 (+0.05%)

As of 04:41 PM Eastern

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Janux Therapeutics NASDAQ:JANX

$18.68 +0.08 (+0.43%)

Closing price 04:00 PM Eastern

Extended Trading

$18.70 +0.02 (+0.09%)

As of 05:42 PM Eastern

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Surrozen NASDAQ:SRZN

$23.36 -0.61 (-2.54%)

Closing price 04:00 PM Eastern

Extended Trading

$23.25 -0.11 (-0.47%)

As of 04:10 PM Eastern

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.

WAVE Life Sciences NASDAQ:WVE

$5.25 +0.13 (+2.54%)

Closing price 04:00 PM Eastern

Extended Trading

$5.22 -0.03 (-0.65%)

As of 04:16 PM Eastern

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SRZN, AVTX, WVE, and JANX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SRZN, AVTX, WVE, and JANX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SRZN, AVTX, WVE, and JANX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRZN, AVTX, WVE, and JANX Company Descriptions

Avalo Therapeutics NASDAQ:AVTX

Janux Therapeutics NASDAQ:JANX

Surrozen NASDAQ:SRZN

WAVE Life Sciences NASDAQ:WVE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SRZN, AVTX, WVE, and JANX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SRZN, AVTX, WVE, and JANX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SRZN, AVTX, WVE, and JANX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRZN, AVTX, WVE, and JANX Company Descriptions

Avalo Therapeutics NASDAQ:AVTX

Janux Therapeutics NASDAQ:JANX

Surrozen NASDAQ:SRZN

WAVE Life Sciences NASDAQ:WVE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools